Cloudbreak Pharma Announces Successful End-of-Phase-2 Meeting and Alignment with FDA on Phase 3 Path Forward for CBT-004

CBT-004, if approved, would be the first and only treatment for pinguecula, an ophthalmic condition impacting more than 50 ...
Ophthalmology Times

Cloudbreak Pharma completes FDA end-of-phase-2 meeting for CBT-004 in pinguecula

CBT-004 is a novel, preservative-free ophthalmic solution targeting VEGF and PDGF receptors to treat vascularized pinguecula. Phase 2 trial results showed significant improvements in conjunctival ...
Healio

Phase 2 trial: Preservative-free eye drop promising for vascularized pinguecula, hyperemia

Please provide your email address to receive an email when new articles are posted on . CBT-004 demonstrated rapid onset of improvement in conjunctival hyperemia. Cloudbreak Pharma is advancing ...